Core Insights - MiNK Therapeutics, Inc. is initiating a Phase 1 clinical trial for its lead therapy, agenT-797, aimed at patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1][2] Group 1: Clinical Trial Details - The trial will assess the safety, tolerability, and preliminary efficacy of agenT-797 in reducing graft-versus-host disease (GvHD), relapse, and other complications in high-risk leukemia and blood cancer patients [2] - The study is led by Dr. Hongtao Liu and co-investigator Dr. Kalyan V. G. Nadiminti from the University of Wisconsin School of Medicine and Public Health [2] Group 2: Funding and Support - The development of agenT-797 is supported by two public-private funding awards: an NIH STTR grant from NIAID and a philanthropic clinical grant, the Mary Gooze Clinical Trial Award [3] - The Mary Gooze Clinical Trial Award funds enrollment, immune monitoring, and operations for the Phase 1 trial, while also supporting mechanistic research on iNKT cells [5] Group 3: Therapeutic Potential - GvHD is a significant cause of morbidity and mortality post-HSCT, affecting up to 50% of recipients, and agenT-797 aims to address this issue without the cytotoxic burden of lymphodepleting conditioning regimens [4] - iNKT cells are positioned to suppress inflammatory responses while maintaining anti-leukemia activity, making them suitable for this therapeutic approach [4] Group 4: Company Overview - MiNK Therapeutics specializes in allogeneic invariant natural killer T (iNKT) cell therapies and aims to develop next-generation immune reconstitution therapies [7][8] - AgenT-797 is designed to be an off-the-shelf, donor-derived therapy that does not require HLA matching or lymphodepletion, enhancing its accessibility for patients [9]

Group 1 - U.S. stock futures are higher, with Nasdaq futures gaining approximately 100 points [1] - Simulations Plus, Inc. reported quarterly earnings of 45 cents per share, exceeding the analyst consensus estimate of 7 cents per share [2] - Simulations Plus reported quarterly sales of $20.363 million, which fell short of the analyst consensus estimate of $20.878 million [2] - Keybanc analyst downgraded Simulations Plus from Overweight to Sector Weight, leading to a 6.3% dip in shares to $16.37 in pre-market trading [2] Group 2 - Presidio Property Trust, Inc. shares fell 29.9% to $9.55 after a significant 166% increase on Monday, following a $2.05 million registered direct offering [4] - MiNK Therapeutics, Inc. shares declined 27.5% to $29.45 after a 37% drop on Monday, with an analyst downgrade from Outperform to Market Perform [4] - Organogenesis Holdings Inc. shares dropped 26.7% to $3.29 after gaining over 4% on Monday [4] - MiMedx Group, Inc. shares fell 20.7% to $5.38 in pre-market trading [4] - Sequans Communications S.A. shares declined 10.8% to $5.01 after a 20% increase on Monday due to Bitcoin acquisition news [4] - Iovance Biotherapeutics, Inc. shares decreased 5.5% to $1.8990 in pre-market trading [4] - FB Financial Corporation shares fell 5.4% to $46.50 following disappointing quarterly sales [4] - ProKidney Corp. shares dropped 4.6% to $3.52 after filing for a common stock offering of up to $200 million [4] - Blue Gold Limited shares declined 4.5% to $26.60 after a 30% surge on Monday [4]

Market Overview - U.S. stock futures are lower, with Dow futures down approximately 100 points on Monday [1] - Ultragenyx Pharmaceutical Inc. shares fell 8% to $27.15 after receiving a Complete Response Letter from the FDA for its gene therapy UX111 [1] Company-Specific Movements - MiNK Therapeutics, Inc. shares dropped 31% to $44.25 after a significant 730% increase on Friday due to a publication announcement [3] - Above Food Ingredients Inc. shares decreased 21.3% to $2.84 following a 134% rise on Friday after announcing a merger agreement [3] - Newegg Commerce, Inc. shares fell 11.3% to $43.66 after a 71% gain on Friday [3] - CEL-SCI Corporation shares declined 11% to $3.08 after an 8% drop on Friday, following a partnership announcement with a Saudi Arabian company [3] - Unusual Machines, Inc. shares slipped 8% to $11.13 after a 39% increase on Friday [3] - Gossamer Bio, Inc. shares fell 6.6% to $1.2700 after completing enrollment in a Phase 3 study for pulmonary arterial hypertension [3] - Gilat Satellite Networks Ltd. shares decreased 4.1% to $7.22 after announcing over $22 million in orders from satellite operators [3] - KalVista Pharmaceuticals, Inc. shares dipped 4% to $13.94 after reporting a wider-than-expected quarterly loss [3] - Apple Inc. shares fell 1% to $209.22 amid a significant management reshuffle, with CEO Tim Cook remaining in charge despite challenges [3]

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index dropping over 250 points, down 0.60% to 44,382.58, while the NASDAQ rose slightly by 0.06% to 20,643.06, and the S&P 500 fell 0.23% to 6,266.23 [1] - European shares were lower, with the eurozone's STOXX 600 dipping 1.07%, Spain's IBEX 35 Index falling 0.99%, London's FTSE 100 down 0.47%, Germany's DAX 40 slipping 0.81%, and France's CAC 40 declining 0.94% [5] - Asian markets closed mixed, with Japan's Nikkei down 0.19%, Hong Kong's Hang Seng up 0.46%, China's Shanghai Composite gaining 0.01%, and India's BSE Sensex falling 0.83% [6] Company Earnings - WD-40 Co. (WDFC) reported better-than-expected earnings for its third quarter, although sales missed estimates. The company raised its FY2025 EPS guidance but narrowed its sales forecast [2] Stock Movements - MiNK Therapeutics, Inc. (INKT) shares surged 526% to $48.40 following a publication in Oncogene [8] - Ruanyun Edai Technology Inc. (RYET) shares increased by 19% to $18.37 after signing a strategic partnership with Confucius Institute at Prince Sultan University [8] - Signing Day Sports, Inc. (SGN) shares rose 98% to $2.4350 due to advancements in its business combination with One BlockchAIn [8] - Milestone Pharmaceuticals Inc. (MIST) shares dropped 41% to $1.5050 after announcing a public offering [8] - Federal Agricultural Mortgage Corporation (AGM) shares fell 11% to $175.20 following the announcement of the departure of its Chief Financial Officer [8] - TransMedics Group, Inc. (TMDX) shares decreased by 10% to $112.93 [8] Commodities - In commodity news, oil prices increased by 2.6% to $68.28, gold rose by 1.5% to $3,375.80, silver gained 4.1% to $38.830, while copper fell by 0.9% to $5.5425 [4]

Core Insights - MiNK Therapeutics, Inc. reported significant business progress and clinical advancements in its fourth quarter and full year 2024 financial results, emphasizing its commitment to developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for challenging cancers and immune-related disorders [1][2] Operational Highlights - The company made substantial clinical strides, enhanced its manufacturing capabilities, and established strategic alliances throughout 2024 [2] - MiNK's rapid AI-driven drug discovery platform is generating a library of phosphorylated neoantigens and proprietary TCRs, positioning the company to set a new standard in oncology [2][6] Clinical Advancements - AgenT-797 demonstrated enhanced immune activation and improved efficacy of checkpoint inhibitors in heavily pretreated patients, with ongoing Phase 2 trials in advanced gastric cancer showing promising early data [7] - The therapy also showed an approximately 80% survival rate in acute respiratory distress patients compared to 10% in hospital controls, with late-stage trials planned [7] - MiNK's PRAME-TCR iNKTs exhibited high specificity and potent tumor-killing capabilities against resistant cancer targets [7] - MiNK-215 (IL-15 Armored CAR-iNKT) displayed robust anti-tumor activity in metastatic colorectal cancer models [7] Strategic Growth and Manufacturing Optimization - MiNK's advanced manufacturing process allows for the production of billions of donor-derived iNKT cells per run, facilitating rapid global distribution and enhancing patient access [7] - The company entered a research collaboration with Autonomous Therapeutics to develop precision RNA-iNKT therapies for metastatic tumors [7] Financial Highlights - MiNK raised $5.8 million in private financing in 2024 and ended the year with a cash balance of $4.6 million [8][9] - Cash used in operations decreased to $1.7 million for Q4 2024 from $3.0 million in Q4 2023, and for the full year, it decreased to $9.6 million from $15.8 million [8][10] - The net loss for 2024 was $10.8 million, or $2.86 per share, a significant reduction from a net loss of $22.5 million, or $6.54 per share, in 2023 [8][12]